CutisPharma Inc. has relocated its headquarters to Wilmington, Mass.


CutisPharma, headquarters, Wilmington, prescription compounding kit, Dr. Indu Muni, pharmacy compounding, compounded drug products


































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

CutisPharma moves to larger facility

May 21st, 2014

WILMINGTON, Mass. – CutisPharma Inc. has relocated its headquarters to Wilmington, Mass.

The prescription compounding kit manufacturer said Wednesday that move to the new headquarters at 841 Woburn St. in Wilmington, from the previous site in Woburn, Mass., puts it in a larger facility.

"We are pleased to announce our relocation to a larger facility to support our record growth," stated Dr. Indu Muni, founder, chairman and chief executive officer of CutisPharma. "The move will help to maintain our expansion, particularly in the areas of research and development, customer service and operations."

Currently, CutisPharma has 24 proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, five Magic Mouthwash kits, three omeprazole suspension kits, three lansoprazole suspension kits and five vancomycin solution kits.

Several more compounding kits are in the planning stages, the company reported.

"Our company mission statement is to simplify the practice of traditional pharmacy compounding and to improve end user's satisfaction for compounded drug products," Muni added.

Advertisement